F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT

Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

23 days / endpoints / Max Gelman

FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

24 days / medicalxpress

What the Health? From KFF Health News: Turnarounds and Shake-Ups

25 days / kffhealthnews

Study shows low vaccination rates among expectant mothers in Norway against COVID-19, influenza

25 days / medicalxpress

FDA reverses course; agrees to review Moderna flu vaccine

26 days / beckershospitalreview / Erica Cerutti

Reversal on Moderna's flu application follows atypical path through FDA

26 days / endpoints / Zachary Brennan

Moderna says the FDA will consider its new flu shot after resolving a public dispute

26 days / abcnews

In reversal, US agrees to review new Moderna flu shot

26 days / medicalxpress

FDA reverses course on Moderna’s flu vaccine

26 days / healthcaredive / Delilah Alvarado

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

26 days / nytimes / Christina Jewett and Rebecca Robbins

FDA reverses course, will review Moderna’s flu vaccine

26 days / endpoints / Max Bayer

Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 26 days



Related Stories



Related Tags


Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare


Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals


Public Health

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

AI improves UK breast-screening detection by about 10% (2 days)

more #publichealth


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.